Online inquiry

IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13606MR)

This product GTTS-WQ13606MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13606MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10143MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ10167MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ15110MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ13952MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ8771MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ5719MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ13862MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ14359MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW